Move fast, but not blind. Aegis gives investors a defensible read on healthcare targets—validating the entire contracts-to-cash engine, reconciling billed vs. collected to expose accrual optimism, and benchmarking payer contracts and rates against the market to size real upside. We surface what decks miss: denial drag, underpayment exposure, system weaknesses, and FWA risk that could follow you post-close. Findings are evidence-first and investor-ready, with cash bridges, rate realization models, and exposure estimates that stand up to scrutiny. You get clear go/no-go signals and a plan that turns diligence into value creation. If you’re not verifying revenue quality and contract strength now, you’re negotiating on hope—and paying for it later.
